• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. (Evidence Syntheses, No. 86.)

Appendix FOngoing and Pending Trials

Principal investigatorsLocationPopulationApproximate sizeInvestigationsOutcomesStatus as of 2010
KQ1: Age to begin screening
KQ2: Liquid-based cytology
KQ3: HPV testing
Coldman*Vancouver, BCRoutine screening
Age 25–69
33,000HPV DNA testing with cytology triage≥ CIN2
≥ CIN3
Cost analysis
Trial expected to finish March 2014
Murphy*Toronto, ONRoutine screening
Aged ≥ 18
1712HPV testing alone or in combination with conventional cytology≥ CIN2
≥ CIN3
Rate of colposcopies
Trial expected to finish January 2011
Ngan*Hong KongRoutine screening
Age 30–60
12,000HPV cotesting with conventional cytology compared to conventional cytology alone≥ CIN2
≥ CIN3
Trial expected to finish January 2017
KQ4: Harms of liquid-based cytology
KQ5: Harms of HPV testing
*

Available at: www​.clinicaltrials.gov. Accessed September 29, 2010.

Available at: www​.clinicaltrials.gov. Accessed September 29, 2010.

Cover of Screening for Cervical Cancer
Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86.
Vesco KK, Whitlock EP, Eder M, et al.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...